Innate Pharma Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: May 12, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | May 12, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, reporting
TL;DR
Innate Pharma filed a routine 6-K, no new info.
AI Summary
Innate Pharma SA filed a Form 6-K on May 12, 2025, reporting a press release dated the same day. The filing does not contain specific financial figures or operational updates beyond the standard reporting requirements for a foreign private issuer.
Why It Matters
This filing indicates Innate Pharma is meeting its SEC reporting obligations as a foreign private issuer, but it does not provide new material information for investors.
Risk Assessment
Risk Level: low — This is a standard SEC filing for a foreign private issuer and does not contain new material information or indicate any unusual events.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- May 12, 2025 (date) — Filing Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public in their home country, or that they have distributed or are required to distribute to their security holders.
What specific information is included in this Innate Pharma 6-K filing?
This filing primarily includes a press release dated May 12, 2025, as Exhibit 99.1, and confirms Innate Pharma's status as a foreign private issuer filing under the 1934 Act.
Does this filing contain any financial results for Innate Pharma?
No, this Form 6-K filing does not contain specific financial results or operational updates; it serves as a notification of a press release.
What is Innate Pharma's principal executive office address?
Innate Pharma's principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Is Innate Pharma required to file annual reports on Form 20-F?
Yes, Innate Pharma indicates with a checkmark that it files or will file annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 12, 2025 regarding Innate Pharma SA (IPHYF).